1999
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment
Elsworth J, Taylor J, Sladek J, Collier T, Redmond D, Roth R. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 1999, 95: 399-408. PMID: 10658619, DOI: 10.1016/s0306-4522(99)00437-6.Peer-Reviewed Original ResearchConceptsHomovanillic acid/dopamine ratioMPTP treatmentStriatal dopamine levelsDopamine levelsDopamine lossDopamine depletionDopamine ratioStriatal subregionsNucleus accumbensCaudate nucleusDopamine concentrationsOne-yearSeverity categoriesDopamine neuron integrityVentromedial caudate nucleusStriatal dopamine lossHomovanillic acid concentrationsStriatal dopaminergic functionMarked increaseNormal motor performancePaucity of dataMetabolic activityNon-human primatesParkinsonian disabilityTetrahydropyridine (MPTP) model
1989
Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions
Elsworth J, Deutch A, Redmond D, Taylor J, Sladek J, Roth R. Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions. Neuroscience 1989, 33: 323-331. PMID: 2622529, DOI: 10.1016/0306-4522(89)90212-1.Peer-Reviewed Original ResearchConceptsHomovanillic acid concentrationsParkinson's diseaseStriatal regionsHomovanillic acid/dopamine ratioGross motor abnormalitiesDepletion of dopamineHomovanillic acid levelsLoss of dopamineIdiopathic Parkinson's diseaseCaudate nucleus dopamineAsymptomatic monkeysTetrahydropyridine (MPTP) treatmentAsymptomatic groupSymptomatic groupDopamine lossTetrahydropyridine (MPTP) toxicityMotor abnormalitiesDopamine ratioCaudate nucleusSignificant negative correlationVentromedial regionStriatum